Proteomic screening and identification of microRNA-128 targets in glioma cells

Proteomics

Volumn 15, Issue 15, 2015, Pages 2602-2617

  Yang, Bin ^a,c   Wang, Shan ^a,d   Zeng, Jiawei ^b,e   Zhang, Yu ^a,f   Ruan, Xiangbin ^a   Han, Wei ^a   Yin, Bin ^a   Yuan, Jiangang ^a   Qiang, Boqin ^a   Ying, Wantao ^b   Qian, Xiaohong ^b   Peng, Xiaozhong ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c FUWAI HOSPITAL   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e Sixth Unit of Internal Medicine   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cell biology; Glioma; MiR 128; PSILAC; Quantitative proteomics

Indexed keywords

AMINO ACID; MICRORNA; MICRORNA 128; STABLE ISOTOPE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN128 MICRORNA, HUMAN; PROTEOME;

ARTICLE; BIOINFORMATICS; BRAIN TISSUE; CONTROLLED STUDY; DATA BASE; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; ISOTOPE LABELING; LUCIFERASE ASSAY; MTT ASSAY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; SCREENING; SITE DIRECTED MUTAGENESIS; TISSUE SECTION; 3' UNTRANSLATED REGION; BRAIN TUMOR; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; GLIOMA; HEK293 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLIOMA; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; ISOTOPE LABELING; MICRORNAS; MICROSCOPY, FLUORESCENCE; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84938572886     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400128     Document Type: Article

References (61)

1. Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A. et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Develop. 2007, 21, 2683-2710.
2. Stupp, R., Mason, W. P., vanden Bent, M. J., Weller, M. et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
3. Taylor, L. P., Diagnosis, treatment, and prognosis of glioma: five new things. Neurology 2010, 75, S28-S32.
4. VanMeir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K. et al., Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA 2010, 60, 166-193.
5. Riddick, G., Fine, H. A., Integration and analysis of genome-scale data from gliomas. Nat. Rev. Neurol. 2011, 7, 439-450.
6. Purow, B., Schiff, D., Advances in the genetics of glioblastoma: are we reaching critical mass? Nat. Rev. Neurol. 2009, 5, 419-426.
7. Zhang, B., Pan, X., Cobb, G. P., Anderson, T. A., microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302, 1-12.
8. Croce, C. M., Calin, G. A., miRNAs, cancer, and stem cell division. Cell 2005, 122, 6-7.
9. Kent, O. A., Mendell, J. T., A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25, 6188-6196.
10. Chen, C. Z., MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 2005, 353, 1768-1771.
11. Iorio, M. V., Croce, C. M., MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2012, 4, 143-159.
12. Ciafrè, S. A., Galardi, S., Mangiola, A., Ferracin, M. et al., Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 2005, 334, 1351-1358.
13. Kwak, H. J., Kim, Y. J., Chun, K. R., Woo, Y. M. et al., Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 2011, 30, 2433-2442.
14. Ernst, A., Campos, B., Meier, J., Devens, F. et al., De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene 2010, 29, 3411-3422.
15. Zhang, J., Han, L., Ge, Y., Zhou, X. et al., miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int. J. Oncol. 2010, 36, 913-920.
16. Gabriely, G., Yi, M., Narayan, R. S., Niers, J. M. et al., Human glioma growth is controlled by MicroRNA-10b. Cancer Res. 2011, 71, 3563-3572.
17. Yin, D., Ogawa, S., Kawamata, N., Leiter, A. et al., miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 2013, 32, 1155-1163.
18. Li, M., Fu, W., Wo, L., Shu, X. et al., miR-128 and its target genes in tumorigenesis and metastasis. Exp. Cell Res. 2013, 319, 3059-3064
19. Chen, G., Zhu, W., Shi, D., Lv, L. et al., MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol. Rep. 2010, 23, 997-1003.
20. Brower, J. V., Clark, P. A., Lyon, W., Kuo, J. S., MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem. Internat. 2014, 77, 68-77.
21. Kato, M., Slack, F. J., microRNAs: small molecules with big roles -C. elegans to human cancer. Biol. Cell 2008, 100, 71-81.
22. Brennecke, J., Stark, A., Russell, R. B., Cohen, S. M., Principles of microRNA-target recognition. PLoS Biol. 2005, 3, e85.
23. Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A. et al., Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433, 769-773.
24. Lewis, B. P., Burge, C. B., Bartel, D. P., Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are MicroRNA targets. Cell 2005, 120, 15-20.
25. Zhang, Y., Chao, T., Li, R., Liu, W. et al., MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J. Mol. Med. 2008, 87, 43-51.
26. Godlewski, J., Nowicki, M. O., Bronisz, A., Williams, S. et al., Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008, 68, 9125-9130.
27. Evangelisti, C., Florian, M. C., Massimi, I., Dominici, C. et al., MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J. 2009, 23, 4276-4287.
28. Papagiannakopoulos, T., Friedmann-Morvinski, D., Neveu, P., Dugas, J. C. et al., Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene 2011, 31, 1884-1895.
29. Shi, Z. M., Wang, J., Yan, Z., You, Y. P. et al., MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS ONE 2012, 7, e32709.
30. Peruzzi, P., Bronisz, A., Nowicki, M. O., Wang, Y. et al., MicroRNA-128 coordinately targets polycomb repressor complexes in glioma stem cells. Neuro-oncology 2013, 15, 1212-1224.
31. Lin, L., Chen, X., Peng, X., Zhou, J. et al., MicroRNA-128 promotes cell-cell adhesion in U87 glioma cells via regulation of EphB2. Oncol. Rep. 2013, 30, 1239-1248.
32. Dong, Q., Cai, N., Tao, T., Zhang, R. et al., An axis involving SNAI1, microRNA-128 and SP1 modulates glioma progression. PLoS ONE 2014, 9, e98651.
33. Baek, D., Villén, J., Shin, C., Camargo, F. D. et al., The impact of microRNAs on protein output. Nature 2008, 455, 64-71.
34. Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z. et al., Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455, 58-63.
35. Großhans, H., Filipowicz, W., Proteomics joins the search for microRNA targets. Cell 2008, 134, 560-562.
36. Schwanhausser, B., Gossen, M., Dittmar, G., Selbach, M., Global analysis of cellular protein translation by pulsed SILAC. Proteomics 2009, 9, 205-209.
37. Kaller, M., Liffers, S. T., Oeljeklaus, S., Kuhlmann, K. et al., Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol. Cell. Proteomics 2011, 10, M111 010462.
38. Cox, J., Mann, M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26, 1367-1372.
39. Cox, J., Matic, I., Hilger, M., Nagaraj, N. et al., A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat. Protoc. 2009, 4, 698-705.
40. Xiao, F., Zuo, Z., Cai, G., Kang, S. et al., miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009, 37, D105-D110.
41. Chopard, A., Pons, F., Charpiot, P., Marini, J. F., Quantitative analysis of relative protein contents by Western blotting: comparison of three members of the dystrophin-glycoprotein complex in slow and fast rat skeletal muscle. Electrophoresis 2000, 21, 517-522.
42. Shannon, P., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498-2504.
43. Cline, M. S., Smoot, M., Cerami, E., Kuchinsky, A. et al., Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2007, 2, 2366-2382.
44. Khan, A. P., Poisson, L. M., Bhat, V. B., Fermin, D. et al., Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol. Cell Proteomics 2010, 9, 298-312.
45. Thal, D. R., Xavier, C. P., Rosentreter, A., Linder, S. et al., Expression of coronin-3 (coronin-1C) in diffuse gliomas is related to malignancy. J. Pathol. 2007, 214, 415-424.
46. Wang, Z. G., Jia, M. K., Cao, H., Bian, P., Fang, X. D., Knockdown of Coronin-1C disrupts Rac1 activation and impairs tumorigenic potential in hepatocellular carcinoma cells. Oncol. Rep. 2013, 29, 1066-1072.
47. Barbato, C., Arisi, I., Frizzo, M. E., Brandi, R. et al., Computational challenges in miRNA target predictions: to be or not to be a true target? J. Biomed. Biotechnol. 2009, 2009, 1-10.
48. Cesana, M., Cacchiarelli, D., Legnini, I., Santini, T. et al., A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147, 358-369.
49. Sumazin, P., Yang, X., Chiu, H.-S., Chung, W.-J. et al., An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma. Cell 2011, 147, 370-381.
50. Tay, Y., Kats, L., Salmena, L., Weiss, D. et al., Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147, 344-357.
51. Karreth, Florian A., Tay, Y., Perna, D., Ala, U. et al., In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 2011, 147, 382-395.
52. Balasubramani, M., Day, B. W., Schoen, R. E., Getzenberg, R. H., Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res. 2006, 66, 763-769.
53. Karni, R., deStanchina, E., Lowe, S. W., Sinha, R. et al., The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 2007, 14, 185-193.
54. Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E. et al., Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011, 476, 346-350.
55. Pollari, S., Kakonen, S. M., Edgren, H., Wolf, M. et al., Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res. Treat. 2011, 125, 421-430.
56. Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C. et al., DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17, 13-27.
57. Theiss, A. L., Jenkins, A. K., Okoro, N. I., Klapproth, J. M. A. et al., Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin 3 expression. Mol. Biol. Cell 2009, 20, 4412-4423.
58. Xu, J., Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2003, 88, 4990-4996.
59. Honoré, B., Baandrup, U., Vorum, H., Heterogeneous nuclear ribonucleoproteins F and H/H′ show differential expression in normal and selected cancer tissues. Exp. Cell Res. 2004, 294, 199-209.
60. Carpenter, B., MacKay, C., Alnabulsi, A., MacKay, M. et al., The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim. et Biophys. Acta 2006, 1765, 85-100.
61. Li, C., Xiong, Q., Zhang, J., Ge, F., Bi, L. J., Quantitative proteomic strategies for the identification of microRNA targets. Exp. Rev. Proteomics 2012, 9, 549-559.